Graves Hyperthyroidism After Stopping Immunosuppressive Therapy in Type 1 Diabetic Islet Cell Recipients With Pretransplant TPO Autoantibodies

PIETER GILLARD, MD, PHD1,2
BRIGITTE DECALLONNE, MD, PHD1
BART VAN DER AUWERA, PHD2
VOLKERT HUURMAN, MD, PHD3
KRIEPOPPÉ, MD, PHD4
BART O. ROEP, PHD3
FRANS GORUS, MD, PHD2
CHANTAL MATHIEU, MD, PHD1
FRANS GORUS, MD, PHD2
DANIEL PIPELEERS, MD, PHD2
BART KEYMEULEN, MD, PHD2

OBJECTIVE — After an initially successful islet cell transplantation, a number of patients return to C-peptide negativity, and therefore immunosuppressive therapy is discontinued. Some are then found to have developed Graves disease. We examined the risk of Graves disease after immunosuppression.

RESEARCH DESIGN AND METHODS — Immunosuppressive therapy was stopped in 13 type 1 diabetic islet cell recipients who had received one course of antithymocyte globulin and maintenance doses of mycophenolate mofetil and a calcineurin inhibitor. None had a history of thyroid disease.

RESULTS — In four patients, clinical Graves hyperthyroidism was observed within 21 months after discontinuation and 30–71 months after the start of immunosuppressive therapy. All four patients exhibited a pretransplant positivity for thyroid peroxidase (TPO) autoantibodies, while the nine others were TPO negative pre- and posttransplantation.

CONCLUSIONS — Type 1 diabetic recipients of islet cell grafts with pretransplant TPO autoantibody positivity exhibit a high risk for developing Graves hyperthyroidism after immunosuppressive therapy is discontinued for a failing graft.

Diabetes Care 32:1817–1819, 2009

Islet cell transplantation has been shown to reproducibly achieve metabolic correction in nonuremic type 1 diabetic patients (1,2). However, in the years following transplantation, several of them return to C-peptide negativity and thus to a discontinuation of their immunosuppressive therapy (2).

RESEARCH DESIGN AND METHODS — Between 1999 and 2002, 17 type 1 diabetic patients (median age 43 years [range 25–56]) received an islet cell graft under one course of antithymocyte globulin (ATG-Fresenius) and maintenance therapy with mycophenolate mofetil (MMF) plus cyclosporine (n = 9) or tacrolimus (n = 8). In 13 of the patients, immunosuppressive therapy was stopped (calcineurin inhibitor first) 6–66 months later because plasma C-peptide levels had dropped under 0.2 ng/dl. They were further monitored for side effects from the intervention protocol.

In terms of autoimmune status, HLA-DQA1-DQB1 and DR3 genotypes and single nucleotide polymorphisms were determined to be susceptibility markers (3, rev. in 4), lymphocytes were phenotyped (5), and autoantibodies (islet cell antibody, insulin antibody, GAD antibody, insulinoma antigen 2 antibody) were measured (6).

Data are presented as median (range). For comparison of patient subgroups, the Mann-Whitney U test was used for quantitative variables and the Fisher's exact test was used for binary variables. Differences were considered significant for P < 0.05.

RESULTS — Clinical Graves disease was diagnosed in 4 of 13 subjects (31%) at 2–21 months after withdrawal of immunosuppressants and 30–71 months after transplantation. Diagnosis was confirmed by suppressed thyrotropin (TSH) levels (<0.01 mIU/l), elevated free thyroxin (20.4–67.7 ng/l; normal 9.3–17.0) and free 3,5,3’-triiodothyronine (6.3–16.9 ng/l; normal 2.6–4.4) levels, and positivity for thyrotropin receptor (TSHR) autoantibodies (3.2–23.8 units/l; normal <1). All the patients exhibited a diffusely increased thyroid technetium-99 uptake (5–17%); normal 1–5).

No differences in pretransplant characteristics were noticed among the four Graves-positive and the nine Graves-negative patients except that all the Graves-positive patients and none of the others were positive for thyroid peroxidase (TPO) autoantibodies (P = 0.001) (Table 1). The Graves-positive patients also tended to be more polymorphic in the protein tyrosine phosphatase nonreceptor type 22 (PTPN22) susceptibility gene (three of four vs. one of nine patients, P = 0.051). There were no differences in age, sex, smoking habits, TSH before transplantation, iodide deficiency status, duration of diabetes, and presence of diabetes-related autoantibodies (data not shown).

The respective doses of immunosuppressants were similar among the Graves-positive and Graves-negative patients: ATG-Fresenius (cumulative median 24.5
Graves hyperthyroidism after islet transplantation

Table 1—Course of thyroid autoantibody positivity in recipients of islet cell grafts developing Graves hyperthyroidism following discontinuation of immunosuppressive therapy

| Pretransplantation (none) | CI and MMF | MMF continued after stopping CI | None after stopping CI and MMF |
|--------------------------|------------|---------------------------------|-------------------------------|
|                         | TPO-Ab | TSHR-Ab | TPO-Ab | TSHR-Ab | TPO-Ab | TSHR-Ab | TPO-Ab | TSHR-Ab |
| Graves (n = 4)           |        |        |        |         |        |         |        |         |
| M.R.                    | +      | –      | –      | –       | + (2)  | + (2)   | +      | +       |
| S.V.                    | +      | –      | –      | –       | –      | –       | + (14) | + (11)  |
| V.G.J.                  | +      | –      | + (3)  | –       | –      | –       | + (8)  | + (8)   |
| R.I.                    | +      | –      | –      | –       | –      | –       | + (8.5)| + (8.5) |
| No Graves (n = 9)       | –      | –      | –      | –       | –      | –       | –      | –       |

The number in parentheses indicates the month at which thyroid antibody positivity was first detected after stopping the calcineurin inhibitor. Ab, antibody; CI, cyclosporine (133 μg/l [114–153] vs. 143 μg/l [112–165], P = 0.69), and daily MMF doses (2.0 g/day [1.0–2.0] vs. 2.0 g/day [1.5–2.0], P = 1.00).

During immunosuppressive therapy, the four TPO autoantibody–positive patients became TPO autoantibody negative and remained so (Table 1). When it was discontinued, TPO autoantibodies reappeared in all four patients with detection at 2 and 14 months after stopping the calcineurin inhibitor (Table 1). In addition, TSHR autoantibodies also appeared in these patients between 2 and 11 months after stopping the calcineurin inhibitor. Of the nine patients that were TPO autoantibody negative before transplantation, none became positive for TPO autoantibodies during an 28- to 85-month follow-up period after discontinuation of the immunosuppressants. All Graves-positive patients also exhibited increases in one or more diabetes-related autoantibodies after drug withdrawal, but this was also the case in six of nine Graves-negative patients (P = 0.49).

**CONCLUSIONS** — We report the development of Graves hyperthyroidism in four type 1 diabetic patients in whom immunosuppressive therapy had been stopped 2–21 months earlier for a failing islet cell graft. These four patients exhibited a pretransplant positivity for TPO autoantibodies without clinical or biochemical signs of thyroid disease. Among the nine recipients who were negative for TPO autoantibodies pretransplantation, none developed Graves hyperthyroidism. TPO seropositivity has been associated with an increased risk for autoimmune hypothyroidism (7) and is present in 60–70% of patients with Graves hyperthyroidism. In type 1 diabetic patients, TPO autoantibodies were found in 30% of patients, but Graves hyperthyroidism was found in only 1–2% (8,9). We now observe that the presence of TPO autoantibodies in type 1 diabetic patients might be predictive for their susceptibility of developing Graves hyperthyroidism after transient immunosuppressive therapy, at least for an islet cell transplant protocol.

Immunosuppressive therapy decreased TPO autoantibody titers under detection levels. Its discontinuation resulted within 21 months with the reappearance of TPO autoantibodies, as well as an appearance of TSHR autoantibodies and clinical signs of hyperthyroidism. We hypothesize that the drug-induced lymphopenia in patients with previously existing occult autoimmune thyroiditis predisposes to a reactivation of autoimmune mechanisms when T-cells are reconstituted after antiretroviral therapy (13).

In our patients, the ATG-induced lymphopenia and subsequent repopulation of T-cells may have altered the immune state leading to an auto-reactivity against thyrocyte antigens such as TSHR. In this respect, the higher frequency of polymorphisms in the PTPN22 susceptibility gene is of interest because it may predispose to the formation of auto-reactive lymphocytes (14). The administration of the calcineurin inhibitor and of MMF probably suppressed the auto-reactivity induced by ATG and its lymphocyte depletion. This is in line with data showing that calcineurin inhibitors efficiently inhibit functions of CD4+ memory phenotype cells (15). Future studies should examine whether slower tapering of the immunosuppressive agents can avoid development of pathogenic autoimmune activities in TPO autoantibody–positive recipients. The use of lower cumulative doses of ATG should also be considered in TPO autoantibody–positive patients, as they would lead to a less pronounced and shorter T-cell depletion.

**Acknowledgments** — This study was supported by a Center Grant from the Juvenile Diabetes Research Foundation (4-2001-434), the Belgium Program on Interuniversity Poles of Attraction initiated by the Belgian State (IAP P/17), and the Fund for Scientific Research-Flanders (FWO). B.K., B.D., and C.M. are Senior Clinical Investigators of FWO.

No potential conflicts of interest relevant to this article were reported.

The authors thank the staff of the Beta Cell Bank, the Belgian Diabetes Registry, the Diabetes Research Center-Vrije Universiteit Brus-
sel, and the Clinical Biology Department of Universitair Ziekenhuis Brussel.

References

1. Shapiro AM, Ricordi C, Hering BJ, Auckincloss H, Lindblad R, Robertson RP, Secchitini A, Bredel MD, Berney T, Brennan DC, Caglieri E, Alejandro R, Ryan EA, DiMercurio B, Morel P, Polonsky KS, Remens JA, Bretzel RG, Bertuzzi F, Frud T, Kandaswamy R, Sutherland DE, Eisenbarth G, Segal M, Preiksaitis J, Korbutt GS, Barton FB, Viviano L, Seyfert-Margolis V, Bluestone J, Lakey JR. International trial of the Edmonton protocol for islet transplantation. N Engl J Med 2006;355:1318–1330

2. Keymeulen B, Gillard P, Mathieu C, Movahedi B, Maleux G, Delvaux G, Ysebaert D, Roep B, Vandemeulebroecke E, Marichal M, In’t Veld P, Bogdani M, Hendrixckx C, Gorus F, Ling Z, van Rood J, Pipeleers D. Correlation between beta cell mass and glycemic control in type 1 diabetic recipients of islet cell graft. Proc Natl Acad Sci USA 2006;103:17444–17449

3. Heimberg H, Nagy ZP, Somers G, De Leeuw I, Schuit FC. Complementation of HLA-DQA and -DQB genes confers susceptibility to protection of insulin-dependent diabetes mellitus. Hum Immunol 1992;33:10–17

4. Jacobson EM, Toner Y. The genetic basis of thyroid autoimmunity. Thyroid 2007;17:949–961

5. Van Bockstaele DR, Deneyes V, Philippe J, Bermeri M, Kestens L, Chatelain B, De Waele C, Demanet C. Belgian consensus recommendations for flow cytometric immunophenotyping: the Belgian Association for Cytometry/Belgische Vereniging voor Cytomterie/Association Belge de Cytometrie. Acta Clin Belg 1999;54:88–98

6. Decoche K, Tits J, Coolens JL, Van Gaal L, Krzetkowsk G, Winnock F, Anckaert E, Weets I, Pipeleers DG, Gorus FK. High frequency of persisting or increasing islet-specific autoantibody levels after diagnosis of type 1 diabetes presenting before 40 years of age: the Belgian Diabetes Registry. Diabetes Care 2000;23:838–844

7. Weetman AP, McGregor AM. Autoimmune thyroid disease: further developments in our understanding. Endocr Rev 1994;15:788–830

8. Leong KS, Wallymahmed M, Wilding J, MacFarlane I. Clinical presentation of thyroid dysfunction and Addison’s disease in young adults with type 1 diabetes. Postgrad Med J 1999;75:467–470

9. Unnikrishnan AG, Kumaravel V, Nair V, Rao A, Jayakumar RV, Kumar H, Sanjeevi CB. TSH receptor antibodies in subjects with type 1 diabetes mellitus. Ann N Y Acad Sci 2006;1079:220–225

10. Khoruts A, Fraser JM. A causal link between lymphopenia and autoimmunity. Immunol Lett 2006;98:23–31

11. Todd A, Todd J. Graves’ disease following successful treatment of severe aplastic anaemia with antilymphocyte globulin. Clin Lab Haematol 1999;21:69–70

12. Coles AJ, Wing M, Smith S, Coradini F, Greer S, Taylor C, Weetman A, Hale G, Chatterjee VK, Waldmann H, Compston A. Pulsed monoclonal antibody treatment and autoimmune thyroid disease in multiple sclerosis. Lancet 1999;354:1691–1693

13. Gilquin J, Viard JP, Juhault V, Sert C, Kazatchkine MD. Delayed occurrence of Graves’ disease after immune restoration with HAART: highly active antiretroviral therapy. Lancet 1998;352:1907–1908

14. Rieck M, Arechiga A, Ongengut-Gumuscu S, Greenbaum C, Concannon P, Buckner JH. Genetic variation in PTPN22 corresponds to altered function of T and B lymphocytes. J Immunol 2007;179:4704–4710

15. Pearl JP, Parris J, Hale DA, Hoffmann SC, Bernstein WB, McCoy KL, Swanson SJ, Mannion RB, Roederer M, Kirk AD. Immune competent T-cells with a memory-like phenotype are the dominant cell type following antibody-mediated T-cell depletion. Am J Transplant 2003;3:465–474